2. Antibody-drug Conjugate/ADC Related
  3. Antibody-Drug Conjugates (ADCs)
  4. Sirtratumab vedotin

Sirtratumab vedotin  (Synonyms: AGS15E; ASG-15ME; 1vcMMAE)

目录号: HY-P99595
技术支持

Sirtratumab vedotin (ASG15-ME) 是一种 ADC，由 SLITRK6 特异性人 γ2 抗体 (Igγ2) 通过蛋白酶可切割连接子偶联到小分子微管干扰剂 monomethyl auristatin E (MMAE)。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Sirtratumab vedotin Chemical Structure

Sirtratumab vedotin Chemical Structure

CAS No. : 1824663-83-3

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 是否有货
1 mg   询价  
5 mg   询价  
10 mg   询价  

* Please select Quantity before adding items.

Customer Review

Sirtratumab vedotin 相关抗体

Top Publications Citing Use of Products

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Sirtratumab vedotin (ASG15-ME) is an ADC composed of a SLITRK6-specific human gamma 2 antibody (Igγ2) conjugated to a small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable linker[1].

体外研究
(In Vitro)

Sirtratumab vedotin (ASG15-ME) 与 SW780 细胞上表达的 SLITRK6 具有高亲和力结合，Kd 为 0.018 nM[1]。
Sirtratumab vedotin (10 μg/mL; 1 h) 与 SLITRK6 结合后内化[1]。
Sirtratumab vedotin (120 h) 抑制 CHP-212 细胞存活，IC50 为 0.99 nM[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Sirtratumab vedotin 相关抗体:

Cell Viability Assay[1]

Cell Line: CHP-212 and IGR-OV1 cells
Concentration:
Incubation Time: 120 h
Result: Showed a dose-dependent inhibition of CHP-212 cell survival with an IC50 of 0.99 nM. Had no effect on IGR-OV1 cells (SLITRK6 negative) when applied at the same concentrations.
体内研究
(In Vivo)

Sirtratumab vedotin (ASG15-ME; 0.25-5 mg/kg; i.v.; 2x per week for 2 or 3 weeks or single dose) 在小鼠的多个异种移植模型中显示出强大的抗肿瘤活性[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: SCID mice, RT4 xenograft model[1]
Dosage: 5 mg/kg
Administration: Intravenous injection, single dose
Result: Caused significant inhibition.
Animal Model: SCID mice, AG-B7 and AG-B8 xenograft model[1]
Dosage: 0.25 and 0.5 mg/kg
Administration: Intravenous injection, 2x per week for 2 or 3 weeks
Result: Significantly reduced tumor volume.
Animal Model: SCID mice, the lung xenograft model NCI-H322M[1]
Dosage: 3 mg/kg
Administration: Intravenous injection, 2x per week for 3 weeks
Result: Was able to cause 99% tumor growth inhibition.
CAS 号
中文名称

纬斯妥尤单抗
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
参考文献

Sirtratumab vedotin 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Sirtratumab vedotin1824663-83-3AGS15E ASG-15ME 1vcMMAE纬斯妥尤单抗Antibody-Drug Conjugates (ADCs)Antibody-Drug ConjugatesSCID miceCHP-212RT4AG-B7AG-B8NCI-H322MInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Sirtratumab vedotin
目录号：
HY-P99595
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z